Cancer Biomarkers Market Revenue to Reach $26.97 Bn, Globally, by 2027 at 11.8% CAGR: Allied Market Research

PORTLAND, Ore., July 29, 2020 /PRNewswire/ -- Allied Market Research published a report titled, "Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, and Glyco-biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Others), and Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027." According to the report, the global cancer biomarkers industry was estimated at $10.94 billion in 2019, and is expected to hit $26.97 billion by 2027, registering a CAGR of 11.8% from 2020 to 2027.

Download Sample Report with Detailed COVID-19 Impact Analysis at: https://www.alliedmarketresearch.com/request-sample/1443

Drivers, restraints, and opportunities-

Prevalence of various types of cancers such as breast, prostate, and lung cancer, development of biological & targeted drug therapies, and reliability of cancer biomarkers fuel the growth of the global cancer biomarkers market. On the other hand, high cost of drug development, threat of failure associated with cancer treatment, and unregulated government regulations & reimbursement policies impede the growth to some extent. However, high-end technological advancements are expected to create multiple opportunities in the industry.

COVID-19 scenario-

• Prevention of cancer by analyzing various cancer biomarkers using different diagnostic methods is an effective approach to obtain quick results for the treatment.So, although a number of industries have been badly affected by the pandemic, the medical diagnostics industry has, quite naturally, not confronted the impacts on a severe note.
• However, the global lockdown has led to postponement of the procedures and accordingly, there's been a short-term decline in the revenue rate in cancer biomarkers market. But, it's expected that the market would experience massive gains through the end of the pandemic.

The omic technologies segment to maintain the lion's share by 2027-

Based on profiling technologies, the omic technologies segment accounted for more than half of the global cancer biomarkers market share in 2019, and is expected to rule the roost by the end of 2027. This is attributed to factors such as rise in use of personalized medicines for cancer treatment and growth in healthcare expenditure among people. The immunoassays segment, on the other hand, would register the fastest CAGR of 16.4% throughout the forecast period, owing to various advantages offered by immunoassays such as simultaneous analysis of multiple compounds, analysis at minute concentrations, and increased efficiency of diagnosis and treatment.

The genetic biomarkers segment to dominate during the estimated period-

Based on biomolecule, the genetic biomarkers segment contributed to nearly half of the global cancer biomarkers market revenue in 2019, and is anticipated to lead the trail till 2027. This is due to its accuracy and precision while detecting cancer and monitoring the effectiveness of the treatment. Simultaneously, the glycol-biomarkers segment would portray the fastest CAGR of 12.5% by 2027. Increase in awareness about the roles of glycosylation and other post translational modifications in cancer biology fuels the segment growth.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/1443

North America to dominate in terms of revenue-

Based on geography, North America held the major share, garnering more than one-third of the global cancer biomarkers market, owing to strong focus on innovation and technological advancements in healthcare & diagnostics in the region. At the same time, Asia-Pacific is expected to manifest the fastest CAGR of 15.1% from 2020 to 2027. This is due to increase in prevalence of cancer, rise in patient awareness, and increase in disposable incomes in the province.

Frontrunners in the industry-

• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Bristol-Myers Squibb Company
• Exact Sciences Corporation
• F.Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Qiagen N.V.
• Merck KGaA
• PerkinElmer, Inc.
• Siemens AG

Access AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) at:

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information: https://www.alliedmarketresearch.com/library-access

Similar Reports:

Immunosuppressants Market - Global Opportunity Analysis and Industry Forecast, 2020–2027

Hybrid Operating Room Market - Global Opportunity Analysis and Industry Forecast, 2019-2026

Neurology Devices market - Global Opportunity Analysis and Industry Forecast, 2019-2026

Digital Diabetes Management Market - Global Opportunity Analysis and Industry Forecast, 2019–2026

Pharmaceutical Drug Delivery Market - Global Opportunity Analysis and Industry Forecast, 2019-2026

U.S. Intraoperative Neuromonitoring Market - Opportunity Analysis and Industry Forecast, 2019–2026

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): 1-800-792-5285, 1-503-894-6022, 1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research 

View original content:http://www.prnewswire.com/news-releases/cancer-biomarkers-market-revenue-to-reach-26-97-bn-globally-by-2027-at-11-8-cagr-allied-market-research-301101974.html

SOURCE Allied Market Research